Study identifier:D081BC00001
ClinicalTrials.gov identifier:NCT01813474
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, open-label study to assess the safety and tolerability of doses of olaparib tablet in Japanese patients with advanced solid malignancies
cancer
Phase 1
No
olaparib
All
23
Interventional
20 Years - 130 Years
Allocation: N/A
Endpoint Classification: Safety
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Dec 2017 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: olaparib tablet monotherapy olaparib tablet | Drug: olaparib tablet oral |